Search
BDR Pharma launches new drug for Philadelphia chromosome-positive leukemia
- OPACC
- Jul 7, 2023
- 1 min read
BDR Pharmaceuticals on Wednesday announced the launch of Nilotinib for a rare subtype of the most common childhood cancer, acute lymphoblastic leukemia.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments